Womed’s fertility-preserving innovation set to roll out across 14 European countries

New barrier device aims to prevent uterine scarring, a common cause of infertility, following gynaecological procedures.

Montpellier-based women’s health company Womed has announced the European rollout of its flagship medical device, ‘Womed Leaf®’, following licensing agreements with distribution partners Kebomed Europe and Saesco Medical. The device will be available in 14 countries across the continent, tackling a long-overlooked cause of female infertility.

Womed Leaf is the first device of its kind designed to prevent intrauterine adhesions (IUAs) — a condition where scar tissue forms inside the uterus, often following procedures such as dilation and curettage (commonly known as a D&C) or fibroid removal surgery. These adhesions can cause the walls of the uterus to stick together, which may lead to infertility, repeated miscarriages, or chronic pelvic pain.

Clinical data suggests IUAs develop in 20% to 45% of such procedures, yet treatment options have long been limited — and often ineffective, with high rates of recurrence.

The Womed Leaf device offers a novel, non-invasive solution. Made from a soft, flexible film, the device is inserted into the uterus at the end of a procedure in a similar manner to an IUD (intrauterine device). Once in place, it gently expands to create a temporary barrier between the uterine walls. This prevents them from sticking together while the tissue heals, before dissolving naturally and painlessly within a week.

Crucially, the device demonstrated high efficacy in a randomised clinical trial (PREG2) involving 160 women with moderate to severe adhesions.

“These partnerships mark the first step of a global launch that will make Womed Leaf the new gold standard in intrauterine adhesion prevention and treatment,” said Gonzague Issenmann, Womed’s Co-founder and CEO.

“Kebomed Europe and Saesco Medical’s established sales networks and expertise in women’s health will help European women and their doctors to preserve or recover their fertility.”

Kebomed Europe will distribute Womed Leaf in eight countries including France, Germany and the Nordic region, while Saesco Medical will cover Spain, Italy, Portugal, and the Benelux nations.

Lars Melbye, Managing Director of Kebomed Europe, welcomed the partnership:

“Womed Leaf addresses a significant unmet need in women's health and we are excited to partner with Womed to bring it to our customers.”

Jordi Fluvia, CEO of Saesco Medical, added:

“Womed is bringing a true innovation in an indication that has been sorely lacking in meaningful improvements for the last two decades.”

The move comes as part of a broader shift toward innovation in uterine health, a field often underserved in both research funding and commercial investment. Womed, which focuses exclusively on conditions affecting the uterus, is among a new wave of medtech companies aiming to close that gap. Other examples include Hera Biotech, which is developing a non-surgical diagnostic for endometriosis and established players such as Hologic and CooperSurgical which have expanded their women’s health portfolios, investing in tools for uterine surgery, fibroid management, and assisted reproductive technologies.